Nephros Inc Stock Price, News & Analysis

Nephros, Inc. (Nasdaq: NEPH) has announced record preliminary net revenue of $10.4 million for fiscal year 2021, marking a 21% increase year-over-year. The fourth quarter also showed strong performance with $2.8 million in revenue, an 18% year-over-year increase. Looking ahead, the company projects 2022 revenue guidance between $13.0 million and $13.5 million, indicating 25-30% growth. With approximately $7 million in cash, Nephros is well-positioned for growth. Full results will be detailed on February 23, 2022.

Nephros, Inc. (Nasdaq: NEPH), a water technology company, announced that CEO Andy Astor will attend the Benchmark Company's 10th Annual One-on-One Discovery Conference on December 2, 2021. This virtual event is invitation-only and designed for institutional clients. Nephros specializes in filtration and pathogen detection solutions for healthcare and commercial markets, aiming to enhance water safety and management.

Nephros, Inc. (NASDAQ: NEPH) reported Q3 2021 financial results with net revenue of $2.6 million, a 24% increase year-over-year. Despite revenue growth, net loss rose to $1.2 million, up 15%. Adjusted EBITDA improved by 22% to ($0.7 million). The company highlighted that year-to-date revenue reached a record high, driven by growth in the water filtration segment, despite challenges from the COVID-19 Delta variant. The FDA is reviewing Nephros’s second-generation HDF system, with expectations for growth in their pathogen detection segment in 2022.

Nephros, a leader in water technology, will release its third quarter financial results on November 4, 2021, post-market. A conference call will be held at 4:30 PM ET on the same day for discussion. Domestic participants can dial 1-844-808-7106, while international callers can reach 1-412-317-5285. A replay of the call will be available until November 11, 2021. Nephros is dedicated to enhancing water safety through its innovative filtration and pathogen detection solutions, serving healthcare and commercial markets.

Nephros, Inc. (Nasdaq: NEPH) reports preliminary Q3 2021 results, anticipating a net revenue of $2.6 million, reflecting a 24% increase year-over-year. Year-to-date revenue reached $7.6 million, marking a 22% increase over the same period in 2020. This quarter marks the third consecutive quarter of growth, averaging 25%. The company's Pathogen Detection Systems segment generated nearly $60,000 in revenue. As of Q3, Nephros holds approximately $7.3 million in cash. Full results will be announced on November 4, 2021.

Nephros, a water technology company, will present at the 14th Annual LD Micro Main Event on October 12, 2021, at 12:30 PM ET in Los Angeles. CEO Andy Astor will lead the presentation, highlighting Nephros's commitment to innovative filtration and pathogen detection solutions for healthcare and commercial sectors. The event showcases micro-cap companies, serving as a vital resource for investors.

For more details, visit LD Micro.

Nephros, Inc. (Nasdaq: NEPH) announced its participation in the 6th Annual MicroCap Leadership Summit on September 24, 2021. The virtual event, hosted by MicroCapClub, gathers over 100 investors worldwide. CEO Andy Astor will present on behalf of Nephros, which was selected as one of ten companies to showcase its innovative water filtration and pathogen detection solutions. This summit aims to connect experienced microcap investors and foster quality discussions on stock ideas.

Nephros, Inc. (Nasdaq: NEPH) has appointed Wes Lobo as Chief Commercial Officer, expanding his role from Chief Marketing Officer, which he held since February 2021. In his new position, Lobo will oversee all commercial strategies and operations, including sales, marketing, and product management. CEO Andy Astor emphasized the need for a cohesive commercial organization to meet customer needs effectively. Lobo expressed excitement for his new role and the growth potential at Nephros, underscoring the company's commitment to water quality solutions.

Nephros reported a 44% increase in net revenue for Q2 2021, totaling $2.3 million, driven by strong performance in their water filtration segment. The company achieved a 35% reduction in net loss, improving to $1.1 million, and an adjusted EBITDA improvement of 46%. The acquisition of GenArraytion, Inc. is expected to enhance capabilities in PCR testing. Additionally, the company submitted their HDF Assist Module for FDA 510(k) clearance, with potential for limited commercial launch later this year.